ScholarLens Back to search
2019•Leukemia & lymphoma/Leukemia and lymphomaRequires access

Designing optimal prognostic models for diffuse large B-cell lymphoma

Colm Keane, Chan Y. Cheah

Open publisher page 0 citations

Abstract

Despite advances in therapy, still up to one third of patients with diffuse large B-cell lymphoma (DLBCL) will ultimately die of their disease. The revised international prognostic index (R-IPI) is...

About this research paper

What this paper is about

Despite advances in therapy, still up to one third of patients with diffuse large B-cell lymphoma (DLBCL) will ultimately die of their disease. The revised international prognostic index (R-IPI) is...

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Despite advances in therapy, still up to one third of patients with diffuse large B-cell lymphoma (DLBCL) will ultimately die of their disease. The revised international prognostic index (R-IPI) is...

Key concepts: Diffuse large B-cell lymphoma, International Prognostic Index, Lymphoma, Medicine, Oncology, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Designing optimal prognostic models for diffuse large B-cell lymphoma — Research Paper | ScholarLens